3 September 2021 (Friday) - ASH Update

The nice people at the American Society for Hematology sent their update today. Perhaps a tad clinical, but background reading is always good stuff. Especially when it doesn’t cost me a penny.

Here are the highlights in acute leukemias:
Flow Cytometry as a Prognostic Tool for Children With Down Syndrome and AML
A recent study published in Blood found that the use of flow cytometry alone to determine measurable residual disease status did not sufficiently identify children with acute myeloid leukemia and Down syndrome who were eligible for reduced treatment intensity.
Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL
Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia included treatment delays and the incidence of hemostatic abnormalities, according to research findings published in Blood Advances.
Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
Treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high rates of complete responses in patients with acute myeloid leukemia, according to results presented at the 2021 ASCO Annual Meeting.

No comments:

Post a Comment